share_log

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)

華盛頓健康諮詢公司維持對NRX製藥的買入評級,將價格目標調整爲19美元(1-10股票拆分)
Benzinga ·  08/05 15:42  · 評級/大行評級

HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19 from $2 (1-10 Reverse Stock Split).

HC Wainwright&Co.分析師Vernon Bernardino認爲NRX製藥(納斯達克股票代碼:NRXP)值得買入,將目標價從2美元(1-10股票回撥拆分)調整至19美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論